Urgencias en psiquiatría - Trastornos de la personalidad, impulsividad, perversiones
D Rodante, F Rebok //
D Rodante, F Rebok // Trastorno límite delapersonalidad • 33. Gagliesi P. [A protocol to assist people with suicidal thoughts in clinical practice]. Vertex. 2010;21(89):42-8. • 34. Oldham J. Integrated treatment planning for borderline personality disorder. In: J EbK, editor. Integrated Treatment of Psychiatric Disorders. Washington, DC: American Psychiatric Publishing; 2001. p. 51-77. • 35. Oldham JM. A 44-year-old woman with borderline personality disorder. Jama. 2002;287(8):1029-37. • 36. Oldham JM. Borderline personality disorder and suicidality. The American journal of psychiatry. 2006;163(1):20-6. • 37. Henry C, Mitropoulou V, New AS, Koenigsberg HW, Silverman J, Siever LJ. Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences. Journal of psychiatric research. 2001;35(6):307-12. • 38. Rebok F, Teti GL, Fantini AP, Cardenas-Delgado C, Rojas SM, Derito MN, et al. Types of borderline personality disorder (BPD) in patients admitted for suicide-related behavior. The Psychiatric quarterly. 2015;86(1):49-60. • 39. O K. Borderline Conditions and Pathological Narcissism. New York: Jason Aronson; 1975. • 40. Zanarini MC, Frankenburg FR. Pathways to the development of borderline personality disorder. Journal of personality disorders. 1997;11(1):93-104. • 41. Siever L. Relationship between impulsivity and compulsivity: a synthesis. In: Oldham JM HE, Skodol AE, editors, editor. Washington, DC.: American Psychiatric Press Inc.; 1996. • 42. Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of general psychiatry. 2006;63(7):757-66. • 43. Stoffers J, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. The Cochrane database of systematic reviews. 2010(6):CD005653. • 44. Council NHaMR. Clinical Practice Guideline for the Management of Borderline Personality Disorder. Melbourne2012. • 45. Tohen M. Pharmacologic treatments for borderline personality disorder. The American journal of psychiatry. 2014;171(11):1139-41. • 46. Bateman AW, Gunderson J, Mulder R. Treatment of personality disorder. Lancet. 2015;385(9969):735-43. • 47. Bender DS, Dolan RT, Skodol AE, Sanislow CA, Dyck IR, McGlashan TH, et al. Treatment utilization by patients with personality disorders. The American journal of psychiatry. 2001;158(2):295- 302. • 48. Pascual JC, Martin-Blanco A, Soler J, Ferrer A, Tiana T, Alvarez E, et al. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. International clinical psychopharmacology. 2010;25(6):349-55. • 49. Paton MB, Large MM. The use of psychoactive drug testing in acute mental health services. Australasian psychiatry: bulletin of Royal Australian and New Zealand College of Psychiatrists. 2015;23(6):710-1. • 50. Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Current psychiatry reports. 2004;6(1):66-70. • 51. Zanarini MC, Frankenburg FR, Reich DB, Conkey LC, Fitzmaurice GM. Treatment rates for patients with borderline personality disorder and other personality disorders: a 16-year study. Psychiatric services. 2015;66(1):15-20. • 52. Silk KR. Management and effectiveness of psychopharmacology in emotionally unstable and borderline personality disorder. The Journal of clinical psychiatry. 2015;76(4):e524-5. • 53. Oldham J. Guideline watch: practice guideline for the treatment of patients with borderline per- EDITORIAL SCIENS 39
NMC Derito // Urgencias en psiquiatría. Trastornosdelapersonalidad, impulsividad, perversiones sonality disorder. Focus 33. 2005;3(3):396-400. • 54. Abraham PF, Calabrese JR. Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? Journal of affective disorders. 2008;111(1):21-30. • 55. Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. The Journal of clinical psychiatry. 2010;71(1):14-25. • 56. Lieb K, Vollm B, Rucker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. The British journal of psychiatry : the journal of mental science. 2010;196(1):4-12. • 57. Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder--current evidence and recent trends. Current psychiatry reports. 2015;17(1):534. • 58. Belli H, Ural C, Akbudak M. Borderline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment. Journal of clinical medicine research. 2012;4(5):301-8. • 59. Pfennig A, Bschor T, Falkai P, Bauer M. The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline. Deutsches Arzteblatt international. 2013;110(6):92-100. • 60. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar disorders. 2013;15(1):1-44. • 61. Ripoll LH. Psychopharmacologic treatment of borderline personality disorder. Dialogues in clinical neuroscience. 2013;15(2):213-24. • 62. New AS, Triebwasser J, Charney DS. The case for shifting borderline personality disorder to Axis I. Biological psychiatry. 2008;64(8):653-9. • 63. Hazlett EA, Zhang J, New AS, Zelmanova Y, Goldstein KE, Haznedar MM, et al. Potentiated amygdala response to repeated emotional pictures in borderline personality disorder. Biological psychiatry. 2012;72(6):448-56. • 64. Garcia-Sabina A, Rabunal Rey R, Martinez-Pacheco R. Review of use of drugs for conditions not included in product characteristics. Farmacia hospitalaria : organo oficial de expresion cientifica dela Sociedad Espanolade Farmacia Hospitalaria. 2011;35(5):264-77. • 65. Soler J, Pascual JC, Tiana T, Cebria A, Barrachina J, Campins MJ, et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3- month randomised controlled clinical trial. Behaviour research and therapy. 2009;47(5):353-8. • 66. Bateman A, Fonagy P. Mentalization based treatment for borderline personality disorder. World psychiatry : official journal of the World Psychiatric Association. 2010;9(1):11-5. • 67. Fonagy P, Bateman AW. Mechanisms of change in mentalization-based treatment of BPD. Journal of clinical psychology. 2006;62(4):411-30. • 68. Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF. Evaluating three treatments for borderline personality disorder: a multiwave study. The American journal of psychiatry. 2007;164(6):922-8. • 69. Kleindienst N KB, Bohus M. Is transference-focused psychotherapy really efficacious for borderline personality disorder? BJP. 2011; 198:156-7. • 70. Giesen-Bloo J, van Dyck R, Spinhoven P, van Tilburg W, Dirksen C, van Asselt T, et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Archives of general psychiatry. 2006;63(6):649-58. • 71. Koons CR RC, Tweed JL, Lynch TR, González AM, Morse JQ, et al. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behav Ther. 2001;32(2):371-90. • 72. Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioral treatment of 40
